Developments: The Rapid Increase in Generic Prices in the UK: A Failure of Competition or Regulation?

Adrian Kay and Darrin Baines

Public Money & Management, 2000, vol. 20, issue 3, 35-38

Abstract: There have been steep rises in the price of some generic drugs since September 1998. These rises have been the subject of an inquiry by the House of Commons Select Committee on Health. This article comments on the pricing of generic drugs and suggests possible solutions to the recent price rises. A fall in the price ofgenerics in the five years prior to September 1998 was a result of regulatory action, rather than strong price competition. However, this regulatory system has now been shown not to have the incentives to encourage suppliers to meet the Government’s objective of cheaper generic drugs. This raises the question of whether cost control strategies for primary care prescribing based on the greater use of generics are reasonable.

Date: 2000
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1111/1467-9302.00221 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:pubmmg:v:20:y:2000:i:3:p:35-38

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/RPMM20

DOI: 10.1111/1467-9302.00221

Access Statistics for this article

Public Money & Management is currently edited by Michaela Lavender

More articles in Public Money & Management from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().